Development of FGFR-based Bispecific ADCs
Displaying 1-1 of 1
| Jan 24th, 01:49 | |
catalieswTotal Topics: 0 Total Posts: 0 |
An appealing and innovative treatment is the bispecific antibody-drug combination (ADC), which delivers targeted cytotoxic drugs with increased efficacy and less non-specific cytotoxic effects while directly targeting tumor-associated cell-surface antigens. Learn more: Development of FGFR-based Bispecific ADCs |
Displaying 1-1 of 1
